(Q34764861)

4 August 2017

1 reference

title

Bupropion: a review of its use in the management of major depressive disorder (English)

1 reference

4 August 2017

2

Lily P H Yang

1 reference

4 August 2017

3

Monique P Curran

1 reference

4 August 2017

1

Sohita Dhillon

1 reference

4 August 2017

publication date

1 January 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

68

1 reference

4 August 2017

issue

5

1 reference

4 August 2017

page(s)

653-689

1 reference

Bupropion in depression. II. The role of metabolites in clinical outcome

4 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868050-00011

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

21 January 2018

2 references

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868050-00011

21 January 2018

12 December 2020

Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment With Bupropion Sustained Release: A Study in Patients With Major Depression

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868050-00011

Double-blind comparison of bupropion and fluoxetine in depressed outpatients

21 January 2018

1 reference

12 December 2020

Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

1 reference

12 December 2020

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

1 reference

12 December 2020

Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression

1 reference

12 December 2020

Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL

1 reference

12 December 2020

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

1 reference

12 December 2020

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

12 December 2020

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 reference

12 December 2020

Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors

1 reference

12 December 2020

Clinical pharmacokinetics of bupropion: a review

1 reference

12 December 2020

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

12 December 2020

Bupropion sustained release: a therapeutic overview

1 reference

12 December 2020

Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects.

1 reference

12 December 2020

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects

1 reference

12 December 2020

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

1 reference

12 December 2020

Effect of bupropion-SR on REM sleep: relationship to antidepressant response

1 reference

12 December 2020

Safety profile of sustained-release bupropion in depression: results of three clinical trials

1 reference

12 December 2020

Bupropion plasma levels and CYP2D6 phenotype

1 reference

12 December 2020

1 reference

12 December 2020

A comparative study of bupropion and amitriptyline in depressed outpatients

1 reference

12 December 2020

Remission of Crohn's disease on bupropion

1 reference

12 December 2020

In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography

1 reference

12 December 2020

Global burden of depressive disorders in the year 2000

1 reference

12 December 2020

Bupropion sustained release: side effect profile.

1 reference

12 December 2020

A 102-center prospective study of seizure in association with bupropion

1 reference

12 December 2020

Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels

1 reference

12 December 2020

REM sleep enhancement by bupropion in depressed men.

1 reference

12 December 2020

Comparison of bupropion and trazodone for the treatment of major depression.

1 reference

12 December 2020

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients

1 reference

12 December 2020

Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression

1 reference

12 December 2020

Bupropion occupancy of the dopamine transporter is low during clinical treatment.

1 reference

12 December 2020

Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine

1 reference

12 December 2020

The medical management of depression

1 reference

12 December 2020

Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation

1 reference

12 December 2020

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

1 reference

12 December 2020

Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?

1 reference

12 December 2020

Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion

1 reference

12 December 2020

A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients

1 reference

12 December 2020

Advances in the treatment of depression

1 reference

12 December 2020

Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials

1 reference

12 December 2020

Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-alpha?

1 reference

12 December 2020

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

1 reference

12 December 2020

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly

1 reference

12 December 2020

Prevalence of sexual dysfunction among newer antidepressants.

1 reference

12 December 2020

Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study

1 reference

12 December 2020

Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression

1 reference

12 December 2020

Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors

1 reference

12 December 2020

Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study.

1 reference

12 December 2020

Bupropion in pregnancy and the prevalence of congenital malformations

1 reference

12 December 2020

Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder

1 reference

12 December 2020

Medication augmentation after the failure of SSRIs for depression.

1 reference

12 December 2020

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

12 December 2020

Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion

1 reference

12 December 2020

Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression

1 reference

12 December 2020

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations

1 reference

12 December 2020

Mechanism of action of antidepressant medications

1 reference

12 December 2020

A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor

1 reference

12 December 2020

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

1 reference

12 December 2020

A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability

1 reference

12 December 2020

Crohn’s disease remission on bupropion

1 reference

12 December 2020

Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response

1 reference

12 December 2020

Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.

1 reference

12 December 2020

Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment

1 reference

12 December 2020

10.2165/00003495-200868050-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1006954054

0 references

1 reference